Subscribe
1 August 2024NewsAmericasMuireann Bolger

Teva asks Fed Circ to reverse inhaler patents loss

Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

More on this story

Big Pharma
Teva secures stay on Orange Book inhaler patent delisting
18 June 2024   New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

More features

Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m